Quality considerations Because IGF-1 LR3 isn't regulated as a pharmaceutical, product quality varies dramatically between sources
Laboratory evidence: A serum B12 level confirming deficiency, or prior documentation of intrinsic factor antibodies for pernicious anemia
The absence of a plausible interaction mechanism no CYP450 involvement, no blood-sugar effects, and poor oral bioavailability means the theoretical risk is low
A comprehensive meta-analysis of eight GLP-1 RA CVOTs revealed several critical findings: 14% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) [3] 13% reduction in cardiovascular death [3] 10% reduction in all-cause mortality [3] 11% reduction in hospitalization for heart failure [3] Post-hoc analyzes from LEADER and SUSTAIN-6 revealed that cardiovascular benefits extended across the spectrum of body mass index categories, indicating efficacy regardless of baseline weight [2]
Since it is suggested that p53, p16, p21 are directly related to the induction of senescence in chondrocytes ( IL-6 and -8 , which however were not detectable due to the low expression level
BPC-157 , 15 ,